Transdermal nitroglycerin in angina pectoris

Abstract

The hemodynamic and antianginal efficacy of transdermal nitroglycerin (TGTN) patches were assessed in patients with chronic, stable angina pectoris. In 11 patients, acute dosing with 10, 20 and 30 cm2 of TGTN (designed to deliver 5, 10 and 15 mg GTN over 24 hours) improved treadmill walking time 2 and 4 hours after application, but no clinical effects were seen at 24 hours. In a second study in 6 patients with doses of 30, 60 and 90 cm2 of TGTN treadmill walking time was improved at 2 and 4 hours, but no changes were seen at 24 hours except with the 90-cm2 preparation. After daily therapy with 30-cm2 patches of TGTN for 1 to 2 weeks, exercise tolerance was similar to that seen during daily placebo therapy. These results suggest that TGTN patches are of inadequate size to produce 24-hour antianginal protection. During sustained therapy, tolerance develops to the antianginal efficacy of this form of GTN administration.